<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02868645</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL15_0336</org_study_id>
    <nct_id>NCT02868645</nct_id>
  </id_info>
  <brief_title>Interest of Serum Periostin Dosage in Patients With Bone Fibrous Dysplasia</brief_title>
  <acronym>PERIOSTINE</acronym>
  <official_title>Interest of Serum Periostin Dosage in Patients With Bone Fibrous Dysplasia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fibrous dysplasia is a rare bone disease which can cause pain and fractures. It has been
      shown that periostin is over expressed in fibrous component in patients bones ; but periostin
      has never been measured out in serum of patients, although it is easy to assess. This study
      aims to show whether serum periostin is elevated in serum of patients with fibrous dysplasia,
      and if it is more elevated in patients with severe forms of the disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 25, 2016</start_date>
  <completion_date type="Anticipated">May 25, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 25, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Periostin rate in serum</measure>
    <time_frame>At inclusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Periostin rate in serum according to the number of fibrotic bones</measure>
    <time_frame>At inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Periostin rate in serum in patients with severe phenotype of the disease</measure>
    <time_frame>At inclusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Periostin rate in serum in patients with Mac Cune Albright syndrome</measure>
    <time_frame>At inclusion</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Bone Fibrous Dysplasia</condition>
  <arm_group>
    <arm_group_label>Patients with bone fibrous dysplasia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with bone fibrous dysplasia will have a blood sampling to assess periostin rate in serum</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control subjects</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control subjects will have no intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>Patients with bone fibrous dysplasia will have blood sampling to assess periostin rate in serum</description>
    <arm_group_label>Patients with bone fibrous dysplasia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with fibrous dysplasia of the bone

          -  access to social security

          -  informed consent

        Exclusion Criteria:

          -  no informed consent

          -  pregnancy

          -  patients with a history of conditions known to increase periostin serum (stade IV
             cancer, severe asthma, pulmonary fibrosis…)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Roland CHAPURLAT, MD, PhD</last_name>
    <phone>+33 4 72 11 74 81</phone>
    <email>roland.chapurlat@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hélène Lemaire, intern</last_name>
    <phone>+33 4 72 11 74 81</phone>
    <email>helene.lemaire@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de rhumatologie Pavillon F - Hôpital Edouard Herriot</name>
      <address>
        <city>Lyon cedex 03</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roland CHAPURLAT, MD, PhD</last_name>
      <phone>+33 4 72 11 74 81</phone>
      <email>roland.chapurlat@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Hélène Lemaire, intern</last_name>
      <phone>+33 4 72 11 74 81</phone>
      <email>helene.lemaire@chu-lyon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Roland CHAPURLAT, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 11, 2016</study_first_submitted>
  <study_first_submitted_qc>August 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2016</study_first_posted>
  <last_update_submitted>February 15, 2018</last_update_submitted>
  <last_update_submitted_qc>February 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrous Dysplasia of Bone</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

